Drug intelligence / Profile preview

VB27

Development stage: Preclinical
Lead developer: Shenzhen Yangli Pharmaceutical Technology
Modality: Small Molecules

Overview

VB27 is a small molecule therapeutic candidate being developed by Zhejiang Yangli Pharmaceutical Technology (VyBio) for the treatment of chronic kidney disease (CKD). As of early 2024, the drug is in the discovery and preclinical stages of development. While the specific molecular target of VB27 remains undisclosed, it is a key component of VyBio's cardiovascular, renal, and metabolic (CVRM) pipeline. The program aims to address unmet medical needs in renal health through a small molecule approach, distinguishing it from other siRNA-based candidates in the company's portfolio.

Beyond the preview

Go deeper on VB27.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB27.

Explore the full profile